BioMarin Closes $850M Senior Unsecured Notes Offering to Fund Amicus Acquisition
Summary
BioMarin Pharmaceutical Inc. announced the closing of its $850 million private offering of 5.500% senior unsecured notes due 2034, a key financing step for its pending acquisition of Amicus Therapeutics, Inc.
Key Events
-
Closing of $850M Notes Offering
BioMarin Pharmaceutical Inc. closed its previously announced private offering of $850 million aggregate principal amount of 5.500% Senior Notes due 2034.
-
Funding for Amicus Acquisition
The net proceeds from the notes offering, along with other debt facilities, will fund the pending acquisition of Amicus Therapeutics, Inc. and related expenses.
-
Escrow and Special Redemption Terms
Gross proceeds are held in an escrow account, with a special mandatory redemption required if the Amicus acquisition is not completed by December 19, 2026.
Analysis
BioMarin Pharmaceutical Inc. announced the closing of its $850 million private offering of 5.500% senior unsecured notes due 2034. This transaction finalizes a significant portion of the debt financing package initiated on January 26, 2026, and priced on January 29, 2026, which is intended to fund the pending acquisition of Amicus Therapeutics, Inc. The gross proceeds from the notes offering have been deposited into an escrow account, with a special mandatory redemption provision if the acquisition is not completed by December 19, 2026. This closing confirms the successful execution of a substantial capital raise, providing necessary funding for the company's strategic M&A activity.
At the time of this filing, BMRN was trading at $59.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.5B. The 52-week trading range was $50.76 to $73.51. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.